The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | Management strategies for advanced systemic mastocytosis
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, comments on the treatment of advanced systemic mastocytosis. Advanced systemic mastocytosis is defined by the presence of C-findings or organ involvement with organ dysfunction. Previously, these patients were treated with agents such as prednisone, hydroxyurea, and interferon. Today, patients are mainly treated with midostaurin and avapritinib, which has recently been approved by the FDA and has been shown to be more effective and tolerable than midostaurin. Ongoing clinical trials are investigating novel agents as well as novel combination strategies to improve the outcomes of patients with systemic mastocytosis. This interview took place virtually.
